Emerald Advisers LLC Grows Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Emerald Advisers LLC raised its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 8.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,125,744 shares of the company's stock after purchasing an additional 165,085 shares during the quarter. Travere Therapeutics accounts for 1.4% of Emerald Advisers LLC's investment portfolio, making the stock its 13th biggest holding. Emerald Advisers LLC owned about 2.72% of Travere Therapeutics worth $37,030,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Finepoint Capital LP increased its stake in Travere Therapeutics by 0.3% in the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company's stock valued at $24,934,000 after buying an additional 5,539 shares during the period. Geode Capital Management LLC lifted its position in Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company's stock valued at $24,222,000 after purchasing an additional 64,744 shares during the period. Parkman Healthcare Partners LLC lifted its position in Travere Therapeutics by 12.0% in the third quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company's stock valued at $15,194,000 after purchasing an additional 116,175 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Travere Therapeutics by 37.1% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 843,300 shares of the company's stock valued at $11,798,000 after purchasing an additional 228,300 shares in the last quarter. Finally, Jennison Associates LLC acquired a new position in Travere Therapeutics during the 4th quarter worth approximately $14,222,000.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TVTX. Evercore ISI upped their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Scotiabank upped their target price on Travere Therapeutics from $27.00 to $32.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research note on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Travere Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $30.62.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 11,375 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the transaction, the chief executive officer now directly owns 419,173 shares of the company's stock, valued at $10,076,918.92. The trade was a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP William E. Rote sold 5,200 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total transaction of $122,356.00. Following the sale, the senior vice president now owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. This represents a 5.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,335 shares of company stock worth $4,453,012. 3.75% of the stock is owned by company insiders.

Travere Therapeutics Trading Down 1.3 %

Shares of TVTX stock traded down $0.28 during mid-day trading on Tuesday, hitting $21.01. 975,519 shares of the company's stock were exchanged, compared to its average volume of 1,419,300. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -5.12 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The stock has a 50-day simple moving average of $20.56 and a two-hundred day simple moving average of $18.30.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Equities analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.